In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...

NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...

This strategy has already resulted in the Sanofi partnership we announced this year, which has enabled us to transition away ...

Novavax Inc (NVAX) reports increased product sales and a strong cash position, while revising revenue guidance and navigating ...

TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...

Novavax's stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for the year ...

Yes, you can get your flu and COVID-19 shots at the same time. Don't call them boosters — they're not just another dose of ...

But COVID-19 tends to jump in the winter months ... The Pfizer and Moderna shots are formulated against a virus subtype ...

People reporting long-COVID symptoms had elevated levels of cytokines ... The FDA concluded that the event was not related to ...

China has reported seven more H9N2 avian flu infections in humans, mostly involving children and all in people whose symptoms ...

2024 Healthcare & Pharmaceuticalscategory Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales November 12, 2024 Healthcare & Pharmaceuticalscategory AstraZeneca lifts 2024 ...

Wall Street's main indexes were little changed on Tuesday following post-election gains over the past few days.